← Back to patent-cliff list
Simmitinib hydrochloride
Tier C — Watch / tradeSimmitinib hydrochloride
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：FGFRs, CSF1R, VEGFR2
Indications (approved)：食管鳞状细胞癌, 食管胃结合部肿瘤, Gastric cancer, Oesophageal cancer, Breast cancer, Solid tumour
Regional status
US
-
EU
-
China
Phase III
2024-09-13
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Simmitinib hydrochloride?
Approved indications include: 食管鳞状细胞癌, 食管胃结合部肿瘤, Gastric cancer, Oesophageal cancer, Breast cancer, Solid tumour.
When does the Simmitinib hydrochloride patent expire?
No public expiry year is available for Simmitinib hydrochloride yet; this page updates once verified.
How do I get a quote for Simmitinib hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01